Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association.

Circulation. 2003 Dec 9;108(23):2941-8. Review. No abstract available.

2.

[Heart failure with thiazolidinedione treatment: what do we know today?].

Erdmann E.

Dtsch Med Wochenschr. 2009 Jan;134(4):154-8. doi: 10.1055/s-0028-1123973. Epub 2009 Jan 15. Review. German.

PMID:
19148858
3.
4.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147
5.

Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.

Patel RR.

Cardiol Rev. 2009 May-Jun;17(3):132-5. doi: 10.1097/CRD.0b013e31819faab2. Review.

PMID:
19384087
6.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
7.

Thiazolidinedione-induced edema in patients with heart failure.

Stroup JS.

Am J Health Syst Pharm. 2007 Dec 1;64(23):2426-30; author reply 2430. No abstract available.

PMID:
18029947
8.

Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C.

J Assoc Physicians India. 2003 Nov;51:1061-4.

PMID:
15260389
9.
10.
11.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R.

Diabetes Care. 2004 Jan;27(1):256-63. Review. No abstract available.

PMID:
14693998
12.

Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?

Buckingham RE, Hanna A.

Diabetes Obes Metab. 2008 Apr;10(4):312-28. doi: 10.1111/j.1463-1326.2006.00700.x. Review.

PMID:
18333890
13.

Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.

Strowig SM, Raskin P.

Diabetes Obes Metab. 2005 Nov;7(6):633-41. Review.

PMID:
16219007
14.

Pioglitazone/metformin (Actoplus met).

[No authors listed]

Med Lett Drugs Ther. 2006 Jan 30;48(1227):9-11. No abstract available.

PMID:
16444136
15.

[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].

Kellerer M, Jakob S, Linn T, Haslbeck M.

MMW Fortschr Med. 2003 Dec 18;145(51-52):I-X; quiz XI-XII. Review. German. No abstract available.

PMID:
14974337
16.

Thiazolidinediones and fluid retention.

Kiryluk K, Isom R.

Kidney Int. 2007 Sep;72(6):762-8. Epub 2007 Jul 18. No abstract available.

17.

Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.

Reyes-Morales H, Mino-León D, Doubova SV, Flores-Hernández S.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):1-9.

PMID:
22192639
18.

[Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].

De Flines J, Scheen AJ.

Rev Med Suisse. 2007 Aug 29;3(122):1876, 1878-83. Review. French.

Supplemental Content

Support Center